Skip to content

Released May 13, 2024, before the open

10-Q filed May 13, 2024, 43 days after period end · 0001171843-24-002785

Q1 2024 · 10-Q
Revenue—
Net Income-$10.79MN/M vs Q1 2023N/M vs Q4 2023
EPS, diluted—
Operating Income-$12,770,000N/M
Operating Cash Flow-$13,888,000N/M
Free Cash Flowderived-$13,888,000N/M

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Net Income-$10.79M-$7.84M-$7.16M-$7.42M
EPS Diluted——-$0.07-$0.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR